Adherence to Phosphodiesterase Type 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension - A Real-World Analysis

PURPOSE: Pulmonary arterial hypertension (PAH) requires chronic pharmacologic therapy and published adherence data are limited on use of phosphodiesterase type 5 inhibitors (PDE5Is) in clinical practice. This study assessed factors associated with adherence to PDE5Is for the treatment of PAH.